Sherbrooke Park Advisers LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Sherbrooke Park Advisers LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 50,092 shares of the biopharmaceutical company’s stock, valued at approximately $1,329,000. Pfizer comprises 0.4% of Sherbrooke Park Advisers LLC’s portfolio, making the stock its 19th largest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer in the fourth quarter worth about $27,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the fourth quarter worth about $28,000. Finally, Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter valued at approximately $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Price Performance

Shares of NYSE PFE opened at $22.57 on Friday. The firm’s 50-day simple moving average is $23.72 and its 200 day simple moving average is $25.40. The stock has a market cap of $128.32 billion, a P/E ratio of 16.01, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.82 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.62%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.